Welch JS, Ley TJ, Link DC, Miller CA, Larson DE, Koboldt DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell. 2012;150:264–78.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Daver N, Schlenk RF, Russell NH, Levis MJ. A review of FLT3 kinase inhibitors in acute myeloid leukemia. Blood. 2019;133:424–37.

Google Scholar 

Perl AE, Altman JK, Cortes J, Smith C, Litzow M, Baer MR, et al. Selective Inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicenter, first-in-human, open-label, phase 1–2 study. Lancet Oncol. 2017;18:1061–75.

Article  CAS  PubMed  PubMed Central  Google Scholar 

European Medicines Agency. Assessment report: Xospata. EMA/545585/2019. 2019.

Perrone S, Imperatore S, Sucato G, Notarianni E, Corbingi A, Andriola C, et al. Gilteritinib and the risk of intracranial hemorrhage: a case series of a possible, under-reported side effect. Ann Hematol. 2023;102:3025–30.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang ES, Montesinos P, Minden MD, Heuser M, Lee JH, Kim HJ, et al. Phase 3 trial of gilteritinib plus Azacitidine vs Azacitidine for newly diagnosed FLT3-mutated AML ineligible for intensive chemotherapy. Blood. 2022;140:1845–57.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gozzo L, Nardo A, Brancati S, Judica A, Duminuco A, Maugeri C, et al. Severe GI toxicity following the use of gilteritinib: a case series and analysis of postmarketing surveillance data. Healthc (Basel). 2023;11:1479.

Google Scholar 

Hamdeh S, Micic D, Hanauer SB. Drug-induced colitis. Clin Gastroenterol Hepatol. 2021;19:1759–79.

Article  CAS  PubMed  Google Scholar 

Zavorka Thomas ME, Lu X, Talebi Z, Jeon JY, Buelow DR, Gibson AA, et al. Gilteritinib inhibits glutamine uptake and utilization in FLT3-ITD–positive AML. Mol Cancer Ther. 2021;20:2207–17.

Article  PubMed  PubMed Central  Google Scholar 

Geer CB, Stasko NA, Rus IA, Lord ST, Schoenfisch MH. Influence of glutathione and its derivatives on fibrin polymerization. Biomacromolecules. 2008;9:1876–82.

Article  CAS  PubMed  Google Scholar 

Suknuntha K, Ramachandran A, Chaturvedi A, Kaushansky K, Deeg HJ, Papayannopoulou T. Megakaryocytic expansion in gilteritinib-treated acute myeloid leukemia patients is associated with AXL Inhibition. Front Oncol. 2020;10:591872.

Article  Google Scholar 

van der Meer JHM, van der Poll T, van ’t Veer C. TAM receptors, Gas6, and protein S: roles in inflammation and hemostasis. Blood. 2014;123:2460–9.

Article  PubMed  Google Scholar 

Patel NM, Srinivas GN, Shukla A, et al. Nonsteroidal anti-inflammatory drug colopathy mimicking malignant masses of the colon: a report of three cases and review of the literature. Gastrointest Endosc. 2005;61:AB102.

Google Scholar 

Ho K, Garcia-Aguilar J, Nagao S, Jacobson I. Colonic mass after NSAID use and concerns for malignancy. ACG Case Rep J. 2023;10:e01151.

Article  PubMed  PubMed Central  Google Scholar 

Baiomi A, Abbas H, Mehershahi S, Daniel M. Non-steroidal anti-inflammatory drugs: a rare cause of colonic mass. Case Rep Gastroenterol. 2021;15:395–9.

Article  PubMed  PubMed Central  Google Scholar 

Meriwether D, Jones AE, Ashby JW, et al. Macrophage COX2 mediates efferocytosis, resolution reprogramming, and intestinal epithelial repair. Cell Mol Gastroenterol Hepatol. 2022;13:1095–120.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zou X, Cao J, Yao Y, Liu W, Chen L. Endoscopic findings and clinicopathologic characteristics of ischemic colitis: a report of 85 cases. Dig Dis Sci. 2009;54:2009–15.

Article  PubMed  Google Scholar 

Khor TS, Lauwers GY, Odze RD, Srivastava A. Mass-forming’ variant of ischemic colitis is a distinct entity with predilection for the proximal colon. Am J Surg Pathol. 2015;39:1275–81.

Article  PubMed  Google Scholar